Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Risk factors for QTc prolongation during amisulpride therapy in schizophrenia

Key clinical point: Renal dysfunction and comedication of amisulpride with clozapine were independently associated with corrected QT (QTc) interval prolongation in patients with schizophrenia.

Major finding: Comedication of amisulpride with clozapine (odds ratio [OR], 3.52; P = .015) and decreased renal function (mild decrease [OR, 3.41; P = .027]; mild-to-moderate decrease [OR, 4.82; P = .016]; and moderate decrease [OR, 13.59; P = .007]) were independently associated with increased risk of QTc prolongation.

Study details: The findings are based on a retrospective study of 271 inpatients with schizophrenia who were orally treated with amisulpride.

Disclosures: The study was supported by grants from the Xiamen Municipal Bureau of Science and Technology planning project and the Natural Science Foundation of Fujian Province. The authors declared no conflicts of interest.

Citation:

Chen B et al. J Clin Psychopharmacol. 2020;40(5):482-486. doi: 10.1097/JCP.0000000000001257.